Mutated trimeric RBD vaccines:a platform against variants of concern

作     者：Belén Aparicio Juan J.Lasarte Pablo Sarobe Belén Aparicio;Juan J.Lasarte;Pablo Sarobe

作者机构：Programa de Inmunología e InmunoterapiaCentro de Investigación Médica Aplicada(CIMACCUN)Universidad de NavarraPamplona31008Spain Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas(CIBEREHD)Pamplona31008Spain IdiSNAInstituto de Investigación Sanitaria de NavarraPamplona31008Spain 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2023年第8卷第5期

页      面：2038-2040页

核心收录：

学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基　　金：supported by Instituto de Salud Carlos III Fondo Europeo de Desarrollo Regional"Una manera de hacer Europa"under grant PI20/00260 Gobierno de Navarra under grant 0011-3597-2020-000024 to PS and by Paula&Rodger Riney Foundation to JJL 

主　　题：vaccine vaccines 

摘      要：He et *** reported in Nature Communications1 the development of a protein vaccine against SASR-CoV-2 Omicron variant consisting of a trimer of the spike protein receptor-binding domain(RBD)of the Delta variant fused to heptad-repeat sequences 1 and *** vaccine induced broad-spectrum neutralizing antibodies and fully protected mice and non-human primates against challenge with live Delta and Omicron virus.